LD-2 disclosure · 4th Quarter - Report
PARKINSON'S ACTION NETWORK
Coverage · No income or expenses were reported on this filing.
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- Medical/Disease Research/Clinical Labs
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
4 issuesEnvironment/Superfund
"S.697, Frank R. Lautenberg Chemical Safety for the 21st Century Act," all sections.
LobbyistsJAMES TUCKER
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
"H.R. 775/S. 539, Medicare Access to Rehabilitation Services Act," all sections;"H.R. 3081/S.1778, The TELE-Med Act, all sections;"H.R. 2624/S. 1488, The Part D Beneficiary Fairness Appeals Act," all sections; "The Veterans E-Health and Telemedicine Support Act," (S. 2170); Medicare support for FDA breakthrough therapies (coalition sign-on support letter)
LobbyistsJAMES TUCKER
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medical/Disease Research/Clinical Labs
"FY 2016 Labor, Health and Human Services, Education, and Related Agencies Appropriations," sections relating to the National Institutes of Health (NIH); "FY 2016 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations," all sections relating to the Food and Drug Administration; "FY 2016 Department of Defense Appropriations," all sections related to the Peer-Reviewed Neurotoxin Exposure Treatment Parkinson's Research (NETPR) program; "The Senate Innovations Initiative," issues related to funding for NIH and FDA, data collection, therapeutic incentives, patient engagement, telehealth, and clinical trials; "H.R. 292/S. 849, The Advancing Research for Neurological Diseases Act," all sections; Consolidated Omnibus Appropriations Act of 2015 (H.R. 2029)
